Key Products And Themes: 3Q Pharma Results Previewed
This article was originally published in Scrip
Earnings season is upon us. Key motifs that will recur in pharma company briefings will include recent rhetoric on drug pricing (with pharma executive likely to emphasize how they are offering real value with innovative therapies); the threat – or for many, such as Amgen, Pfizer or Boehringer Ingelheim, the opportunity – of biosimilars given that a slew of blockbuster monoclonal antibodies are reaching or nearing loss of exclusivity; and the negative impact of currency trends on US dollar-reporting firms' sales and earnings. The perennial favorite of analyst question time, M&A intentions, will surely rear its head more than once, too.
Register for our free email digests: